Cited 8 times in
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2023-07-25T04:56:27Z | - |
dc.date.available | 2023-07-25T04:56:27Z | - |
dc.date.issued | 2023-06 | - |
dc.identifier.issn | 1083-7159 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195585 | - |
dc.description.abstract | Background: The MORPHEUS platform comprises multiple open-label, randomized, phase Ib/II trials designed to identify early efficacy and safety signals of treatment combinations across cancers. Atezolizumab (anti-programmed cell death 1 ligand 1 [PD-L1]) was evaluated in combination with PEGylated recombinant human hyaluronidase (PEGPH20). Methods: In 2 randomized MORPHEUS trials, eligible patients with advanced, previously treated pancreatic ductal adenocarcinoma (PDAC) or gastric cancer (GC) received atezolizumab plus PEGPH20, or control treatment (mFOLFOX6 or gemcitabine plus nab-paclitaxel [MORPHEUS-PDAC]; ramucirumab plus paclitaxel [MORPHEUS-GC]). Primary endpoints were objective response rates (ORR) per RECIST 1.1 and safety. Results: In MORPHEUS-PDAC, ORRs with atezolizumab plus PEGPH20 (n = 66) were 6.1% (95% CI, 1.68%-14.80%) vs. 2.4% (95% CI, 0.06%-12.57%) with chemotherapy (n = 42). In the respective arms, 65.2% and 61.9% had grade 3/4 adverse events (AEs); 4.5% and 2.4% had grade 5 AEs. In MORPHEUS-GC, confirmed ORRs with atezolizumab plus PEGPH20 (n = 13) were 0% (95% CI, 0%-24.7%) vs. 16.7% (95% CI, 2.1%-48.4%) with control (n = 12). Grade 3/4 AEs occurred in 30.8% and 75.0% of patients, respectively; no grade 5 AEs occurred. Conclusion: Atezolizumab plus PEGPH20 showed limited clinical activity in patients with PDAC and none in patients with GC. The safety of atezolizumab plus PEGPH20 was consistent with each agent's known safety profile. (ClinicalTrials.gov Identifier: NCT03193190 and NCT03281369). | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | AlphaMed Press | - |
dc.relation.isPartOf | ONCOLOGIST | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adenocarcinoma* / drug therapy | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects | - |
dc.subject.MESH | Carcinoma, Pancreatic Ductal* / drug therapy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hyaluronoglucosaminidase / adverse effects | - |
dc.subject.MESH | Paclitaxel / adverse effects | - |
dc.subject.MESH | Pancreatic Neoplasms* / drug therapy | - |
dc.subject.MESH | Pancreatic Neoplasms* / pathology | - |
dc.subject.MESH | Stomach Neoplasms* / drug therapy | - |
dc.title | Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Andrew H Ko | - |
dc.contributor.googleauthor | Kyu-Pyo Kim | - |
dc.contributor.googleauthor | Jens T Siveke | - |
dc.contributor.googleauthor | Charles D Lopez | - |
dc.contributor.googleauthor | Jill Lacy | - |
dc.contributor.googleauthor | Eileen M O'Reilly | - |
dc.contributor.googleauthor | Teresa Macarulla | - |
dc.contributor.googleauthor | Gulam A Manji | - |
dc.contributor.googleauthor | Jeeyun Lee | - |
dc.contributor.googleauthor | Jaffer Ajani | - |
dc.contributor.googleauthor | Maria Alsina Maqueda | - |
dc.contributor.googleauthor | Sun-Young Rha | - |
dc.contributor.googleauthor | Janet Lau | - |
dc.contributor.googleauthor | Nedal Al-Sakaff | - |
dc.contributor.googleauthor | Simon Allen | - |
dc.contributor.googleauthor | Danny Lu | - |
dc.contributor.googleauthor | Colby S Shemesh | - |
dc.contributor.googleauthor | Xinxin Gan | - |
dc.contributor.googleauthor | Edward Cha | - |
dc.contributor.googleauthor | Do-Youn Oh | - |
dc.identifier.doi | 10.1093/oncolo/oyad022 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J02415 | - |
dc.identifier.eissn | 1549-490X | - |
dc.identifier.pmid | 36940261 | - |
dc.subject.keyword | PD-L1 | - |
dc.subject.keyword | basket study | - |
dc.subject.keyword | combination therapy | - |
dc.subject.keyword | gastric cancer | - |
dc.subject.keyword | hyaluronan | - |
dc.subject.keyword | immunotherapy | - |
dc.subject.keyword | pancreatic cancer | - |
dc.subject.keyword | proof of concept | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | 라선영 | - |
dc.citation.volume | 28 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 553 | - |
dc.citation.endPage | e472 | - |
dc.identifier.bibliographicCitation | ONCOLOGIST, Vol.28(6) : 553-e472, 2023-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.